Dr Burton added that Moderna is due to file for regulatory approval for the variant jab 'within days' and this included the UK.
The stage is set. Time to rise. Mode RNA
Once again, confirms my belief that this company really knows what it's doing.
'We’ve talked with public health bodies in the UK, I think there is definite interest in 214 (the variant vaccine),' he said.
The new jab is a bivalent vaccine meaning it contains material from both the original Covid strain and the Omicron variant.
Moderna has already created hundreds of millions of doses of its vaccine, meaning if approved it could be rapidly distributed.
Responding to the Moderna data Professor Penny Ward, pharmaceutical expert at King's College London, welcomed the findings.
'The data suggest that the bivalent booster might confer greater protection against the BA.4 and BA.5 omicron strains than re-administering the original vaccine to increase protection across the population,' she said.
While she added the full data of the study needs to be seen, the new jab could prove a vital tool against Covid in the coming months.
'As we head towards the autumn with Omicron variants dominating the Covid infection landscape, it certainly makes sense to consider use of this new bivalent vaccine, if available, for the UK autumn Covid booster campaign,' she said.
Moderna has also said it is preparing the data from the trial for peer review.
The data comes as the NHS urged people who had not yet come forward for their spring booster to get their jab.
More than five million invited were sent out to people over the age of 75, care home residents or people aged 12 and over who have a weakened immune system.
